| Overview |
| bs-2661R-Cy7 |
| MD1 Polyclonal Antibody, Cy7 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Rat |
| Human, Mouse, Dog, Cow, Pig, Rabbit |
| Specifications |
| Cy7 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human LY-86 |
| 65-162/162 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 9450 |
| Secreted |
| BPAD; dJ80N2.1; LY86; LY-86; LY 86; Lymphocyte antigen 86; Lymphocyte antigen 86 precursor; Major affective disorder 1; MD-1; MD1; MD 1; MD1 protein; MD1 RP105 associated; MD1 RP105 associated; MMD-1; RP1-80N2.1. |
| MD1 is a 28 kDa molecule that is associated at the cell surface with RP105 (CD180). RP105 is a leucine-rich repeat (LRR) molecule that is expressed on B lymphocytes. It was first identified by a mAb that protects spleen B cells from irradiation-induced apoptosis. LRR proteins, such as Toll receptors, have a role in innate immunity. MD1 is primarily expressed by B cells, dendritic cells and monocytes, and promotes the recognition of, and subsequent signaling by LPS in the innate immune system. MD1 does not have any homology to other molecules. MD1 when expressed alone behaves as a secretory protein. Expression of MD1 in a cell increases the expression of RP105. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz